Report
Thomas J. Schiessle
EUR 190.00 For Business Accounts Only

China fasst Tritt, Q3 (April-Juni) entscheidet über Gj. 19-20

Das Q2/19-20 (€ 345 Mio.; nom. +0,5 %; EBIT-Marge 13,2 % (Vj.: 18,1 %)) hatte sich – wenig überraschend – stark eingetrübt. Die Lage in Europadrehte“ sich - im Q1 war ein Zuwachs von 11 %, im Q2 ein Rückgang von 11 % zu verzeichnen. In Asien verlangsamte sich das Wachstum von 22 % in Q1 auf 4,4 %. Zum Ende hin (März) wurden die COVID-19-Belastungen zunehmend auch in den Kundenregionen EMEA und Americas spürbar, wohingegen in China die Aktivitäten wieder zügig aufgenommen wurden.

Underlying
Carl Zeiss Meditec AG

Carl Zeiss Meditec is a holding company. Co.'s businesses are focused on two primary areas: Ophthalmology and Microsurgery. In Ophthalmology, Co.'s operations are divided in to two strategic business units: Ophthalmic Systems, which includes a range of laser and diagnostic systems for ophthalmology; and Surgical Ophthalmology, which consists of activities in the field of ophthalmic implants and consumables. In Microsurgery, Co. provides surgical microscopes and visualization solutions, e. g. for ear, nose and throat surgery, or neurosurgery. These products are mainly used to assist with the removal of tumors, as well as the treatment of vascular diseases and functional disorders.

Provider
EQUITS GmbH
EQUITS GmbH

EQUI.TS GmbH is an innovative, equity research boutique based in Frankfurt (Germany). It is operated by its original founders and has established a reputation as a quality research provider over a period of more than 10 years. Although it generally does not focus on any particular branch of industry, its analyses often revolve around technology and growth stocks.

Analysts
Thomas J. Schiessle

Other Reports on these Companies
Other Reports from EQUITS GmbH
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch